Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4999834 | 0.96 | CDC7 (0.40) | CDC7MEN1KMT2APIM1PIM2 | |
| SCHEMBL4991902 | 0.95 | CDC7 (0.43) | CDC7MEN1KMT2APIM1PIM2 | |
| SCHEMBL4999813 | 0.93 | CDC7 (0.41) | CDC7MEN1KMT2APIM1PIM2 | |
| SCHEMBL5000323 | 0.91 | CDC7 (0.42) | CDC7MEN1KMT2APIM1PIM2 | |
| SCHEMBL4997589 | 0.90 | CDC7 (0.41) | CDC7MEN1KMT2APIM1PIM2 | |
| SCHEMBL4991786 | 0.90 | CDC7 (0.42) | CDC7MEN1KMT2APIM1PIM2 | |
| SCHEMBL4991823 | 0.89 | CDC7 (0.40) | CDC7PIM1PIM2POLBS1PR1 | |
| SCHEMBL4997398 | 0.89 | CDC7 (0.40) | CDC7MEN1KMT2APIM1PIM2 | |
| SCHEMBL4995460 | 0.88 | ALDH1A1 (0.41) | CDC7MEN1KMT2APIM1PIM2 | |
| SCHEMBL14188684 | 0.86 | CDC7 (0.46) | CDC7MEN1KMT2APIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MKNK2, MAPKAPK2, MAP3K2 | CDC7 487/4885MEN1 2627/4885KMT2A 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.